Glyco-MAP: a quick, multi-test platform to profile antibody responses to glycosylated mucin proteins
Official title: Glyco-MAP: a high-throughput multiplexed platform for Glycosylated Mucin Antibody Profiling with glycoengineered cell lines expressing well-defined homogeneous glycostructures
Funded at Arizona State University-Tempe Campus · NIH-11411433 · Data updated 2026-11-12
A new, fast test platform will map autoantibody responses to specially engineered mucin proteins that mimic cancer-related sugars, helping detect cancer earlier.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arizona State University-Tempe Campus NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | September 9, 2025 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $220,193 |
| NIH project number | 5R21CA296660-02 |
| Project ID | NIH-11411433 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients at risk for cancer or with suspicion of cancer who could benefit from earlier detection biomarkers.
✕Less likely to help
Healthy individuals with no cancer risk may have limited direct benefit from this platform.
What this research studies
This project uses specially engineered cell lines to create mucin proteins with defined sugar structures and a high-throughput assay to profile antibodies in many samples at once. By applying these glycoengineered proteins in a multiplexed format, researchers aim to identify cancer-associated antibody patterns that could serve as early detection biomarkers. The approach combines advanced glycoengineering with a scalable testing method to better understand TAAbs in cancer. If successful, this platform could accelerate biomarker discovery and improve early cancer screening options.
Why it matters
Potential benefit: If proven effective, the platform could enable earlier cancer detection through blood-based antibody biomarkers.
How similar studies have gone: Previous TAAb studies lacked post-translationally modified targets, making this glycoengineered approach a novel but building on TAAb biomarker work.
Where this research is happening
-
Arizona State University-Tempe Campus
Scottsdale, United States Active
Researchers
- Principal investigator: Qiu, Ji — Arizona State University-Tempe Campus
- Study coordinator: Qiu, Ji
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.